TRX319 + Bendamustine for Multiple Sclerosis

(IMPACT-MS Trial)

This trial tests a new treatment called TRX319 for individuals with primary progressive or secondary progressive Multiple Sclerosis (MS), both of which worsen over time. The study aims to determine the safety of TRX319, the optimal dose, and whether using Bendamustine (a chemotherapy medication) beforehand is beneficial. Participants will engage for up to a year, undergoing blood tests and scans like MRIs to assess the treatment's effects. This trial may suit those who have experienced worsening MS symptoms in the past two years. As a Phase 1/Phase 2 trial, the research focuses on understanding how TRX319 works in people and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking MS treatment development.

The trial protocol does not specify if you need to stop taking your current medications. However, if you have been treated with certain therapies like CD20-depleting antibodies, Bruton's tyrosine kinase inhibitors, or sphingosine 1 phosphate modulators, you may need to wait for a specific period before starting the trial.

Previous studies have shown that TRX319 holds promise for treating progressive forms of multiple sclerosis (MS). It helps balance the immune system by specifically targeting certain B cells, a type of immune cell. Research indicates that TRX319 is generally well-tolerated, though it may have side effects like any treatment. Ongoing studies continue to gather more safety information.

Bendamustine, used before the main treatment, has approval for other conditions, such as certain types of cancer. It has known side effects, including the risk of serious skin reactions and low blood cell counts. Its safety is well-documented due to its long-standing use in medicine.

Researchers are excited about TRX319 in combination with Bendamustine for treating Multiple Sclerosis because it represents a novel approach compared to traditional options like interferons or monoclonal antibodies. Unlike these standard treatments, which primarily aim to modulate the immune system or target specific proteins, TRX319 potentially offers a new mechanism of action by enhancing neural repair and reducing inflammation at its source. This dual-action capability could lead to more effective management of Multiple Sclerosis symptoms and progression. Additionally, the combination with Bendamustine, known for its efficacy in certain cancers, may provide synergistic benefits, potentially offering a more comprehensive treatment strategy.

Research has shown that TRX319, a new cell therapy, might help treat progressive forms of Multiple Sclerosis (MS). It calms B and T cells, parts of the immune system that can cause damage in MS. Early studies demonstrated that TRX319 can also reduce certain signals in the body that cause inflammation. In this trial, some treatment arms use Bendamustine to prepare the body for more effective TRX319 action. Although more information is needed, these early findings suggest that TRX319 could be promising for people with primary or secondary progressive MS.⁶⁷⁸⁹¹⁰